Literature DB >> 11683876

Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2.

V Kirkin1, R Mazitschek, J Krishnan, A Steffen, J Waltenberger, M S Pepper, A Giannis, J P Sleeman.   

Abstract

VEGF-C and VEGF-D are lymphangiogenic factors that bind to and activate VEGFR-3, a fms-like tyrosine kinase receptor whose expression is limited almost exclusively to lymphatic endothelium in the adult. Processed forms of VEGF-C and VEGF-D can also activate VEGFR-2, a key player in the regulation of angiogenesis. There is increasing evidence to show that these receptor-ligand interactions play a pivotal role in a number of pathological situations. Inhibition of receptor activation by VEGF-C and VEGF-D could therefore be pharmaceutically useful. Furthermore, to understand the different roles of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in pathological situations it will be necessary to dissect the complex interactions of these ligands and their receptors. To facilitate such studies we cloned, sequenced and characterized the expression of rat VEGF-C and VEGF-D. We showed that Cys152-->Ser mutants of processed rat VEGF-C can activate VEGFR-3 but not VEGFR-2, while the corresponding mutation in rat VEGF-D inhibits its ability to activate both VEGFR-2 and VEGFR-3. We also synthesized and characterized indolinones that differentially block VEGF-C- and VEGF-D-induced VEGFR-3 kinase activity compared to that of VEGFR-2. These tools should be useful in analysing the different activities and roles of VEGF-C, VEGF-D and their ligands, and in blocking VEGFR-3-mediated lymphangiogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683876     DOI: 10.1046/j.1432-1033.2001.02476.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  25 in total

1.  Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation.

Authors:  Min Xu; Mb Majella Doyle; Babak Banan; Neeta Vachharajani; Xuanchuan Wang; Nael Saad; Kathryn Fowler; Elizabeth M Brunt; Yiing Lin; William C Chapman
Journal:  J Am Coll Surg       Date:  2017-04-09       Impact factor: 6.113

2.  Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate.

Authors:  Giacomo Azzali
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism.

Authors:  Jerome W Breslin; Sarah Y Yuan; Mack H Wu
Journal:  Lymphat Res Biol       Date:  2007       Impact factor: 2.589

4.  Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.

Authors:  Rui Benedito; Susana F Rocha; Marina Woeste; Martin Zamykal; Freddy Radtke; Oriol Casanovas; Antonio Duarte; Bronislaw Pytowski; Ralf H Adams
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

5.  The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1.

Authors:  Nicholas E Vlahakis; Bradford A Young; Amha Atakilit; Dean Sheppard
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

6.  Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression.

Authors:  Romina Mancinelli; Paolo Onori; Eugenio Gaudio; Antonio Franchitto; Guido Carpino; Yoshiyuki Ueno; Domenico Alvaro; Luigi P Annarale; Sharon Demorrow; Heather Francis
Journal:  Exp Biol Med (Maywood)       Date:  2009-02-20

7.  Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.

Authors:  Masaki Matsuura; Mitsuho Onimaru; Yoshikazu Yonemitsu; Hanako Suzuki; Toshiaki Nakano; Hiroaki Ishibashi; Kanemitsu Shirasuna; Katsuo Sueishi
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

8.  Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1.

Authors:  Michael J Flister; Andrew Wilber; Kelly L Hall; Caname Iwata; Kohei Miyazono; Riccardo E Nisato; Michael S Pepper; David C Zawieja; Sophia Ran
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

9.  VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.

Authors:  Ingrid Nilsson; Fuad Bahram; Xiujuan Li; Laura Gualandi; Sina Koch; Malin Jarvius; Ola Söderberg; Andrey Anisimov; Ivana Kholová; Bronislaw Pytowski; Megan Baldwin; Seppo Ylä-Herttuala; Kari Alitalo; Johan Kreuger; Lena Claesson-Welsh
Journal:  EMBO J       Date:  2010-03-11       Impact factor: 11.598

10.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.